علاج مرض بيروني عندما تكون الأعراض مستقرة لمدة لا تقل عن ثلاثة أشهر وتكون الصلابة القضيبية كافية

References

In the patient with stable disease, symptoms have been clinically quiescent or unchanged for at least three months based on either patient report or clinician documentation.

Clinicians may administer intralesional collagenase clostridium histolyticum in combination with modeling by the clinician and by the patient for the reduction of penile curvature in patients with stable Peyronie's disease, penile curvature >30° and <90°, and intact erectile function (with or without the use of medications).

Clinicians may administer intralesional interferon α-2b to patients with Peyronie's disease.

Clinicians may offer intralesional verapamil for the treatment of patients with Peyronie's disease.

At one year of follow-up, in the collagenase groups, curvature was reduced by mean 17 degrees. Average curvature reduction was 13.5 degrees in the interferon group compared to 4.5 degrees in the placebo group. Average plaque size reduction was 2.6 cm² in the interferon group compared to 0.9 cm² in the placebo group. Penile pain resolved in 21 of 31 (67.7%) patients in the interferon group who reported pain at baseline but in only 9 of 32 (28.1%) of patients in the placebo group who entered the study with pain.